NGNE
Neurogene Inc. Health Care Pharmaceutical Preparations Russell 3000
$27.55Close
$426.7MMarket cap
$16.37 – $42.8452-week range
Nov 12, 2026Next report
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Lagging the market RS 47 · weaker than 53% of stocks over 12 months
- Far from its high 36% below its 52-week high
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
36%
1wk
up 17.0%
price change
1mo
down 1.0%
price change
12-month return
down 17%
market up 11% ·
its own down 27%
F-score
—
— Not assessed
Altman Z
8.97
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.6×
price / book
Earnings yield
down 32.0%
EBIT / enterprise value
Cheaper than
29%
of the market · expensive
Revenue growth
down 100%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 31%
return on equity
Free cash margin
—
-$78.4M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
9.0%
$2.47 a day · 2×ATR $22.62
RS
47 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.05
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 4.3% over the year, from 15m to 15m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 100.0% over the year.
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026+1% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $925,000 | $0 |
| Operating income | -$33.7M | -$60.7M | -$56.5M | -$55.6M | -$82.6M | -$103.3M |
| Net income | -$33.3M | -$60.7M | -$55.2M | -$36.3M | -$75.1M | -$90.4M |
| Net margin | — | — | — | — | -8124% | — |
| Earnings per share | -$12.84 | -$22.05 | -$19.99 | — | -$4.28 | -$4.24 |
| Free cash flow | -$26.8M | -$50.8M | -$55.1M | -$51.7M | -$71.4M | -$78.4M |
| Free cash margin | — | — | — | — | -7720% | — |
| Cash | $192.6M | $142.5M | $82.0M | $148.2M | $136.6M | $103.8M |
| Shareholders' equity | $191.2M | -$91.9M | -$145.7M | $186.0M | $310.4M | $264.9M |
| Shares outstanding | 2.11m | 2.12m | 0 | 12.82m | 14.85m | 15.49m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 24, 2026 | Annual ↗ | Dec 31, 2025 | 83d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Mar 24, 2025 | Annual ↗ | Dec 31, 2024 | 83d |
| Nov 18, 2024 | Quarterly ↗ | Sep 30, 2024 | 49d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Mar 18, 2024 | Annual ↗ | Dec 31, 2023 | 78d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 11, 2026 | Results ↗ |
| Jul 2, 2026 | Material agreement · Other events ↗ |
| Jun 29, 2026 | Regulation FD · Other events ↗ |
| Jun 8, 2026 | Regulation FD ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| May 12, 2026 | Results ↗ |
| Apr 20, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 24, 2026 | Results ↗ |
| Feb 26, 2026 | Regulation FD ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Nov 13, 2025 | Results ↗ |
| Nov 12, 2025 | Regulation FD ↗ |